{"id":"NCT03691831","sponsor":"Aclaris Therapeutics, Inc.","briefTitle":"A Study of A-101 Topical Solution for the Treatment of Common Warts","officialTitle":"A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study of A-101 Topical Solution Applied Twice a Week in Subjects With Common Warts","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-09-13","primaryCompletion":"2019-04-21","completion":"2019-07-09","firstPosted":"2018-10-02","resultsPosted":"2020-10-05","lastUpdate":"2020-10-27"},"enrollment":502,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Common Wart"],"interventions":[{"type":"DRUG","name":"Active","otherNames":["hydrogen peroxide 45%"]},{"type":"OTHER","name":"Vehicle","otherNames":["isopropyl alcohol and sterile water"]}],"arms":[{"label":"Active","type":"ACTIVE_COMPARATOR"},{"label":"Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"Phase 3 Study of A-101 Topical Solution in Subjects with Common Warts","primaryOutcome":{"measure":"The Primary Efficacy Endpoint is the Number of Subjects Whose Identified Common Warts Are Determined to be Clear on the PWA Scale (PWA=0) at Visit 10 (Day 60)","timeFrame":"Day 60","effectByArm":[{"arm":"Active","deltaMin":33,"sd":null},{"arm":"Vehicle","deltaMin":8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0001"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":24,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":251},"commonTop":["Application site pain","Application site pallor","Application site erythema","Application site pruritus","Application site scab"]}}